JPWO2019241802A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019241802A5
JPWO2019241802A5 JP2021519532A JP2021519532A JPWO2019241802A5 JP WO2019241802 A5 JPWO2019241802 A5 JP WO2019241802A5 JP 2021519532 A JP2021519532 A JP 2021519532A JP 2021519532 A JP2021519532 A JP 2021519532A JP WO2019241802 A5 JPWO2019241802 A5 JP WO2019241802A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
proliferative
proliferative cells
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021519532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527713A (ja
JP2021527713A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037559 external-priority patent/WO2019241802A2/en
Publication of JP2021527713A publication Critical patent/JP2021527713A/ja
Publication of JP2021527713A5 publication Critical patent/JP2021527713A5/ja
Publication of JPWO2019241802A5 publication Critical patent/JPWO2019241802A5/ja
Priority to JP2024109073A priority Critical patent/JP2024153667A/ja
Pending legal-status Critical Current

Links

JP2021519532A 2018-06-15 2019-06-17 増殖性細胞を抑制する方法 Pending JP2021527713A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024109073A JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685866P 2018-06-15 2018-06-15
US62/685,866 2018-06-15
PCT/US2019/037559 WO2019241802A2 (en) 2018-06-15 2019-06-17 Methods of inhibiting proliferative cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024109073A Division JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Publications (3)

Publication Number Publication Date
JP2021527713A JP2021527713A (ja) 2021-10-14
JP2021527713A5 JP2021527713A5 (https=) 2022-06-27
JPWO2019241802A5 true JPWO2019241802A5 (https=) 2022-06-27

Family

ID=67138135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519532A Pending JP2021527713A (ja) 2018-06-15 2019-06-17 増殖性細胞を抑制する方法
JP2024109073A Pending JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024109073A Pending JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Country Status (4)

Country Link
US (1) US20210371855A1 (https=)
EP (1) EP3806850A2 (https=)
JP (2) JP2021527713A (https=)
WO (1) WO2019241802A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013120A (es) 2018-06-04 2021-07-21 Broad Inst Inc Tratamiento terapéutico de cánceres de microsatélites inestables.
JP7714162B6 (ja) * 2018-12-03 2025-09-08 タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法
AR122534A1 (es) 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
JP2024508841A (ja) * 2021-02-25 2024-02-28 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ プログラム可能なタンパク質分解のための化合物及び疾患処置のための使用方法
JP7753397B2 (ja) * 2021-05-26 2025-10-14 ノバルティス アーゲー ウェルナー症候群ＲｅｃＱヘリカーゼ（ＷＲＮ）の阻害に関連する疾患を治療するためのトリアゾロ－ピリミジン類似体
WO2023062575A1 (en) * 2021-10-14 2023-04-20 Ideaya Biosciences, Inc. Cyclic vinyl sulfone compounds as wrn inhibitors
KR20250034120A (ko) * 2022-07-06 2025-03-10 비비디온 테라퓨틱스, 인코포레이티드 Wrn 헬리케이스 억제제를 포함하는 약제학적 조성물
TW202421158A (zh) 2022-11-18 2024-06-01 瑞士商諾華公司 藥物組合及其用途
WO2024140597A1 (zh) * 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Wrn解旋酶抑制剂
CN120603834A (zh) * 2023-01-18 2025-09-05 成都微芯药业有限公司 双杂环wrn抑制剂、其制备方法及其应用
WO2024153244A1 (zh) * 2023-01-20 2024-07-25 南京再明医药有限公司 含氮类化合物
WO2024215923A2 (en) * 2023-04-11 2024-10-17 Nimbus Wadjet, Inc. Cyclic vinyl sulfone wrn inhibitors
WO2024235844A1 (en) * 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
TW202510857A (zh) * 2023-06-01 2025-03-16 英商葛蘭素史密斯克藍智慧財產權有限公司 化合物及其用途
WO2025026382A1 (zh) * 2023-08-01 2025-02-06 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025106693A1 (en) * 2023-11-16 2025-05-22 Eikon Therapeutics, Inc. Methods and compositions for treating cancers with high microsatellite instability levels
WO2025131978A1 (en) * 2023-12-20 2025-06-26 Nerviano Medical Sciences S.R.L. Drug-linker reagents for conjugation
WO2025237361A1 (zh) * 2024-05-16 2025-11-20 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025239377A1 (ja) * 2024-05-16 2025-11-20 株式会社ジーンケア研究所 ＷＲＮヘリカーゼ遺伝子を標的とするｓｉＲＮＡ
WO2025252190A1 (en) * 2024-06-07 2025-12-11 Cullgen Inc. Targeted degraders of werner syndrome recq helicase

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372772B1 (en) * 1997-08-01 2002-04-16 Prolx Pharmaceuticals Corporation Inhibitors of redox signaling and methods of using same
WO2002024692A1 (en) * 2000-09-20 2002-03-28 Karolinska Innovations Ab 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
US6448080B1 (en) * 2001-02-23 2002-09-10 Isis Pharmaceuticals, Inc. Antisense modulation of WRN expression
US7659278B2 (en) * 2002-02-21 2010-02-09 Aprea Ab Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
EP1761629A2 (en) * 2004-05-19 2007-03-14 Trustees Of Boston University Modulation of wrn-mediated telomere-initiated cell signaling
WO2011014825A2 (en) * 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
JP5762103B2 (ja) * 2011-04-13 2015-08-12 国立大学法人滋賀医科大学 頭頸部癌及び食道癌用抗癌剤及び増強剤
EP2836606B1 (en) * 2012-04-10 2021-12-29 Vib Vzw Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway
CA2951816A1 (en) * 2013-06-12 2014-12-18 Oncoimmunin, Inc. Systemic in vivo delivery of oligonucleotides
US20190185849A1 (en) 2016-06-29 2019-06-20 Crispr Therapeutics Ag Compositions and methods for gene editing
US11530413B2 (en) * 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
MX2020013120A (es) * 2018-06-04 2021-07-21 Broad Inst Inc Tratamiento terapéutico de cánceres de microsatélites inestables.
JP7753397B2 (ja) * 2021-05-26 2025-10-14 ノバルティス アーゲー ウェルナー症候群ＲｅｃＱヘリカーゼ（ＷＲＮ）の阻害に関連する疾患を治療するためのトリアゾロ－ピリミジン類似体

Similar Documents

Publication Publication Date Title
JP2021527713A5 (https=)
JPWO2019241802A5 (https=)
JP2023123863A (ja) ナノ粒子としてのｔＲＮＡ送達用組成物およびその使用方法
EP3691620B1 (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
Arifuzzaman et al. Selective inhibition of EZH2 by a small molecule inhibitor regulates microglial gene expression essential for inflammation
Hassan et al. MicroRNA-122 mimic/microRNA-221 inhibitor combination as a novel therapeutic tool against hepatocellular carcinoma
CN107074807A (zh) 用于抑制组蛋白脱甲基酶的组合物和方法
JPWO2019213516A5 (https=)
CN110582581A (zh) 用于治疗过度增殖性疾病的方法中的atr激酶的抑制剂
Park et al. In vivo therapeutic genome editing via CRISPR/Cas9 magnetoplexes for myocardial infarction
Boyle et al. Targeting DNA mismatches with rhodium metalloinsertors
Serda et al. Glycofullerenes as non-receptor tyrosine kinase inhibitors-towards better nanotherapeutics for pancreatic cancer treatment
EP3697767B1 (en) Compounds and methods for treating cancer
CN107502654A (zh) 用于实体瘤靶向用药指导的多基因富集和检测方法
Kitagawa et al. Inhibition of glucose-6-phosphate dehydrogenase activity attenuates right ventricle pressure and hypertrophy elicited by VEGFR inhibitor+ hypoxia
TW200410690A (en) Topical treatment of skin diseases
JP2021514979A5 (https=)
Wotawa et al. Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells
Song et al. A “controlled assembly” strategy for constructing Coptidis Rhizoma self-assembled nanoparticles to ameliorate inflammatory damage in atopic dermatitis
Heidenreich et al. Targeted therapy in patients with metastatic male germ cell tumors
CN115803031A (zh) 用于癌症治疗的贝伐非尼
TWI910994B (zh) 一種RNA m6A調控劑組合物及其製備方法與應用
RU2820200C2 (ru) Способ терапии глиомы человека за счет снижения пролиферации и индукции дифференцировки опухолевых клеток глиомы человека
JPWO2023114875A5 (https=)
Sanjuvikasini et al. CRISPR/Cas9 Technology: Making Possibilities against Breast Cancer